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1. Introduction 
ABO antigens are composed of sugar chains and exist not only on red cells but also on many 
other cells including endothelial cells and epithelial cells of various organs such as kidney, 
heart, bowel, lung, and pancreas (Marionneau et al., 2001). ABO antibodies, which have 
been called as isoagglutinins, are preformed antibodies directed against missing A or B 
antigens. The source of anti-A/B antibodies is thought to be gastrointestinal and 
environmental bacteria, such as the enterobacteriaceae, which possess ABO-like structures 
on their lipopolysaccharide coats (Yamamoto, 2004). These preformed ABO antibodies are 
clinically important in transfusion and organ transplantation medicine because they can 
cause acute hemolytic transfusion reaction in ABO-incompatible (ABO-I) blood transfusion 
and hyperacute rejection in ABO-I organ transplantation. 
 
 
 
Fig. 1. Proposed mechanism of hyperacute rejection in ABO-incompatible organ 
transplantion. 
Hyperacute rejection is induced by the binding of anti-A/B to antigens expressed on the 
endothelial cells of the ABO-I graft and activation of complement system (Fig. 1). 
Subsequently, endothelial damage, inflammation and platelet aggregation can be provoked, 
leading to vascular thrombosis, occlusion of blood supply and rejection.  
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ABO-I kidney transplantations were first reported in late 1950s and early 1960s (Hume et al., 
1955; Murray et al., 1960; Starzl et al., 1964; Kissmeyer-Nielsen et al., 1966). These early 
experiences showed that hyperacute rejection could occur, and therefore, crossing the ABO 
barrier was excluded in the field of kidney transplantation. 
In 1981, Slapak et al. first introduced the concept of depleting anti-A/B antibodies when 
they used modified plasmapheresis and successfully overcame the major donor-recipient 
blood group incompatibility in kidney transplant patient. Later, the same group reported on 
pre-transplantation immunoadsorption and plasmapheresis for ABO-I kidney 
transplantation, showing a high survival rate of 87% (Slapak et al., 1990). 
Another group also started a living donor ABO-I kidney transplantation program in 1982, 
after this group inadvertently experienced an ABO-I cadaver kidney transplantation due to 
an error in donor ABO typing. In spite of the A1 to O major ABO-incompatibility, the kidney 
graft from ABO-I cadaver functioned well with a basic immunusuppressive regimen 
including a short course of polyclonal antibody with azathioprine, and has been reported to 
be still functioning 22 years later (Squifflet et al., 2004). In this group, plasmapheresis was 
chosen to remove antibodies before transplantation and to prevent the occurrence of 
antibody-mediated hyperacute rejection. In addition, the immunosuppressive regimen was 
started 3 days prior to transplantation, and splenectomy was performed on the day of 
transplantation (Alexandre et al., 1985a, 1985b, 1986). Although the transplantation was 
successful, the return and persistence of anti-donor blood-group antibody was observed in 
spite of chronic immunosuppression. However, even with the continued presence of these 
antibodies and the persistence of the target antigen in the kidney, most of the graft 
continued to function well (Alexandre et al., 1991; Cardella et al., 1987; Reding et al., 1987).  
It was suggested that ABO blood group incompatibility need not be an absolute barrier to 
successful kidney transplantation. 
2. Accommodation 
It has been observed that ABO-I kidney grafts functioned well without rejection in recipients 
having high titers of anit-A/B antibodies. This phenomenon has been termed 
accommodation and regarded as an acquired resistance of an organ to immune-mediated 
damage (Bach et al., 1997; Lynch & Platt, 2008, 2010; Platt et al., 1990). In accommodation 
state, the graft is not pathologically injured despite the presence of circulating anti-donor 
antibodies. 
The mechanism of accommodation is yet to be elucidated. It was postulated that 
accommodation might be involved in change in antibodies, change in antigen, modified 
control of complement, or acquired resistance to injury (Lynch & Platt, 2008). Complement 
regulation was thought to be essential for the survival of transplants over time and thus for 
accommodation to be manifested. C4d deposition without signs or symptoms of rejection 
can be observed in accommodated kidney (Lynch & Platt, 2010). The occurrence of 
complement activation means that antibody binding is intact in accommodated kidneys, and 
the lack of lysis means that some regulatory pathways are working for graft survival in the 
accommodation.  
Three possible outcomes of the binding of complement-fixing alloantibody to endothelial 
cells have been postulated (Colvin & Smith, 2005). Hyperacute or acute rejection can be 
resulted, if the complement is fully activated. Accommodation can be achieved, if 
complement activation is completely inhibited. Incomplete inhibition of complement might 
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be sufficient to prevent cell lysis but not to prevent complement activation, leading to 
endothelial cell activation and chronic antibody-mediated rejection (AMR). 
Studies in mice showed that, in the absence of T-cell help, B cells that are exposed to 
incompatible carbohydrate antigens on allografts differentiate into cells that can produce 
non-complement-fixing antibody, and these B cells gradually become tolerant after 
prolonged exposure (Ogawa et al., 2004). 
An acquired resistance to injury could reflect accommodation more comprehensively, but 
does not exclude other mechanisms. Actually, such resistance or protection could be 
appreciated, if some antibodies bind to graft and some complements are activated. Park et 
al. (2003) used microarrays, and compared five 1-year protocol ABO-compatible renal graft 
biopsies to four accommodated ABO-I graft biopsies. They identified significant alterations 
in gene expression in 440 probe sets, including SMADs, protein tyrosine kinases, TNF-alpha 
and Mucin 1. They concluded that accommodation is always present in well-functioning, 
long-surviving ABO-I kidney transplants. Regarding this self-protection against antibody-
mediated damage, several novel mechanisms were suggested including the disruption of 
normal signal transduction, attenuation of cellular adhesion, and the prevention of 
apoptosis. 
Accommodation is regarded as a good response to transplantation. It prevents acute 
antibody-mediated injury, thus allowing chronic process to ensue over time. 
Accommodation can be induced when antibodies that would cause rejection of a graft are 
removed from a recipient and then later return. In addition to this induced type, 
accommodation can occur spontaneously, without depleting antibodies. In this regard, the 
prevalence of accommodation would be higher than expected, and spontaneous 
accommodation may be the most common outcome of clinical organ transplantation (Tang 
& Platt, 2007). Accommodation still remains an evolving concept, and has a mixed support 
from experimental and clinical findings. The most important unanswered questions are how 
often and by which mechanisms accommodation occurs (Lynch & Platt, 2010). 
Accumulation of clinical evidences and research data would bring progress in 
understanding the biological implications of accommodation. 
3. Current practice 
The earlier works in the early 1980s were expanded greatly in Japan, where ABO-I kidney 
transplantation has been performed in more than 1,000 patients since 1989, and recently 
accounts for about 18% of all living donor kidney transplants (Takahashi, 2007). Later, a 
number of centers in USA and Europe have begun ABO-I kidney transplantations using 
similar protocols (Crew & Ratner, 2010). 
The clinical outcome of ABO-I kidney transplantation improved remarkably in the last 10-15 
years since the routine use of tacrolimus and mycophenolate. Clinical literatures repeatedly 
showed that ABO-I kidney transplantation has outcomes comparable to ABO-compatible 
kidney transplantation (Haidinger et al., 2009; Jeon et al., 2010; Kenmochi et al., 2008; Oettl 
et al., 2009; Thielke et al., 2007). One-year and five-year survival rates of ABO-I kidney 
transplants showed little difference from those of ABO-compatible kidney transplants, and 
their renal functions based on creatinine levels also showed no difference. Recently, the 
Japanese data on 851 ABO-I kidney transplantations was summarized (Tanabe, 2007a). 
According to this report, 1-, 3-, 5-, and 10-year patient survivals have been 95%, 92%, 90%, 
and 85%, respectively, whereas 1-, 3-, 5-, and 10-year graft survivals have been 89%, 85%, 
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79%, and 61%, respectively. These improved outcomes are attributed to a clearer 
understanding of the mechanisms underlying accommodation and acute AMR, permitting 
the development of new therapeutic strategies. There were significant differences in graft 
survival and the incidence of rejection before and after the introduction of 
tacrolimus/mycophenolate mofetil. 
3.1 Induction therapies 
Initial protocols for ABO-I kidney transplantation included splenectomy, which was 
performed in most recipients until 2004. Recently, a monoclonal antibody directed against 
CD20 on B cells, rituximab, has replaced splenectomy in most centers (Fig. 2). The use of 
rituximab eliminated the need for additional surgical intervention, and the outcomes with 
rituximab infusion alone were equal to those with splenectomy, providing more evidence 
that splenectomy is unnecessary (Crew & Ratner, 2010; Tanabe et al., 2009).  
 
 
 
Fig. 2. Changes of preconditioning protocols for ABO-incompatible kidney transplantation. 
Between 1989 and 1999, a triplicate immunosuppressive regimen consisted of tacrolimus or 
cyclosporine A plus azathioprine or mizoribine plus methylprednisolone. Since 2000, 
tacrolimus, mycophenolate mofetil, and methylprednisolone have been used. Splenectomy 
was performed until 2004, and recently anti-CD20 antibody (rituximab) became an 
alternative to splenectomy. In most cases, 3-7 sessions of plasmapheresis or 
immunoadsorption have been performed before transplantation. 
Rituximab as an alternative to splenectomy markedly reduced the incidence of AMR and 
greatly improved the results, becoming a clinically proven effective regimen for a successful 
ABO-I kidney transplantation. Interestingly, one recent study reported excellent outcomes 
without splenectomy or rituximab, questioning whether rituximab is indeed necessary 
(Segev et al., 2005). The authors suggested that rapid allograft accommodation may limit the 
need for long-term antibody suppression provided by splenectomy or anti-CD20, thereby 
eliminating the added infectious risk of these modalities and removing another disincentive 
to ABO-I transplantation. 
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Before 2000, a triplicate immunosuppressive regimen consisting of tacrolimus or 
cyclosporine A plus azathioprine or mizoribine plus methylprednisolone was mainly used. 
Thereafter, tacrolimus, mycophenolate mofetil, and methylprednisolone were used at most 
institutions. A greater incidence of acute rejection that was observed during the cyclosporine 
A era was markedly reduced in the tacrolimus era. In particular, the routine use of 
tacrolimus and mycophenolate mofetil significantly reduced acute rejection rates in patients 
with high-pretransplant isoagglutinin titers, and improved their outcomes to the levels 
comparable to those with low titers (Ishida et al., 2007). 
3.2 Antibody reduction therapies 
In all protocols, plasmapheresis to reduce and control anti-A or –B titers is a central feature. 
In most cases, ABO-I kidney transplantation recipients underwent 3-7 sessions of 
plasmapheresis (therapeutic plasma exchange) or double-filtration plasmapheresis before 
transplantation to reduce isoagglutinin titers. Plasmapheresis effectively removes anti-ABO 
antibodies, and approximately 20% of reduction is expected in each treatment. Its side 
effects, which are observed in approximately 5% of patients, are mainly hypocalcemia and 
pruritus/urticaria, and are usually mild and well tolerated (Tobian et al., 2008, 2009).     
Plasmapheresis removes not only ABO antibodies but also the other protective antibodies or 
clotting factors, potentially increasing the risk of perioperative infection or bleeding. In 
contrast to plasmapheresis, immunoadsorption method can selectively remove anti-ABO 
antibodies, unaffecting the levels of the other plasma proteins. The blood type-specific 
columns can effectively remove anti-A or anti-B antibodies, and approximately 30% of anti-
A/B IgM and 20% of anti-A/B IgG levels can be removed after a single treatment (Valli et 
al., 2009). In spite of its physiologic technique and successful clinical applications, the high 
cost of immunoadsorption column is a major limiting factor blocking its widespread use. 
The absence of randomized trials, which compared plasmapheresis and immunoadsorption, 
makes precise comparison of cost and outcomes impossible at the current point. 
Plasmapheresis is a form of therapy to separate plasma from a person’s circulating blood, 
removing pathogenic substances in plasma, and returning the remainder to the patient, 
usually with replacement fluids. The removal of a pathologic substance is affected by its 
concentration in circulating blood, the processing volume of blood and the degree of 
intravascular distribution. For example, IgM or fibrinogen are efficiently removed due to 
their predominantly intravascular distribution compared to IgG, which is predominantly 
extravascular. The alteration of immunoglobulin after single-plasma volume exchange was 
reported as about 63% decrease from baseline (Orlin & Berkman, 1980). An example of the 
changes of anti-A and anti-B antibody titers and creatinine levels before and after ABO-I 
kidney transplantation is shown in Fig. 3 (Moon et al., 2009). Efficiency of antibody removal 
is variable according to the patients. It is important that recipients or potential recipients of 
ABO-I kidneys should receive plasma that contains no ABO antibody against the graft for 
transfusion or plasmapheresis. 
Plasmapheresis is indicated in various diseases such as thrombotic thrombocytopenic 
purpura, myasthenia gravis, or hyperviscosity in monoclonal gammopathy. Regarding 
indication for plasmapheresis, The American Society for Apheresis (ASFA) has published 
the guidelines and recommendations (Szczepiorkowski et al., 2010). According to this ASFA 
guideline, ABO-I kidney transplantation is classified as category II, in which plasmapheresis 
is generally accepted but considered to be supportive or adjunctive to other, more definite 
treatments, rather than a primary first-line therapy.  
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Fig. 3. An example of the changes of anti-A/anti-B antibody titers and creatinine levels 
before and after ABO-incompatible kidney transplantation. The patient’s blood type was O, 
Rh+ and the donor’s blood type was B, Rh+. A combination therapy with plasmapheresis, 
intravenous gammaglobulin, rituximab and potent immunosuppression was performed. 
Although the patient’s baseline anti-A and anti-B titers were relatively low (1:16 for both 
anti-A and anti-B), titers were successfully decreased after each plasmapheresis procedure 
(average 1 fold), finally decreased to 1:1. The kidney transplantation was successful without 
any sign of hyperacute or acute rejection (modified from the refernece by Moon, et al (2009) 
with permission of Korean Journal of Laboratory Medicine). 
Generally, plasmapheresis is performed using automated instruments. These instruments 
have specialized devices for blood withdrawal, anticoagulation, separation, return of blood, 
replacement and discard or collection of separated substances. The separation process is 
performed by centrifugation or filtration. In centrifugation method, blood components are 
separated by specific gravity and divided as plasma, platelets, leukocytes and red blood 
cells. In filtration method, blood is passed through a filter, and blood components are 
separated by their differences in particle size. Filtration and centrifugation can be combined 
by using rotating filter.   
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In conventional plasmapheresis, smaller proteins such as albumin are also removed in 
addition to pathogenic molecules, antibody or high molecular weight proteins. In general, 
plasma separated with a plasma separator is discarded and replaced with the same volume 
of replacement fluid such as fresh frozen plasma or albumin solution. There are several 
options of plasmapheresis, which separate blood components more selectively.  
Double filtration plasmapheresis (DFPP) uses two filters which have different pore sizes. In 
the first filter, blood is separated as plasma and cell components, and plasma is further 
separated by the second filter. Large molecular-weight proteins including immunoglobulins 
such as anti-donor isoagglutinins are removed, while smaller molecular-weight substances 
such as albumin are returned to the patient’s circulation. In this procedure, need of 
replacement is decreased compared with conventional plasmapheresis, thus adverse effects 
related to the replacement fluid can be reduced (Fig. 4) (Genberg et al., 2010; Tanabe, 2007b).  
In the immunoadsorption, specialized adsorption column selectively adsorbs a specific 
substance such as immunoglobulin or low-density lipoprotein. This process removes the 
element of interest specifically and the remaining elements are returned to the patients. 
Many kinds of immunoadsorption devices for the removal of various types of components 
are commercially available but generally expensive. For the removal of anti-A and -B 
antibody, AB antigen-specific carbohydrate columns (Glycosorb AB, Glycorex 
Transplantation AB, Lund, Sweden) were developed (Tyden et al., 2005) and have been 
widely used in more than 400 cases of ABO-I kidney transplantation (Genberg et al., 2010; 
Tyden et al., 2005; Winters et al., 2004). This procedure could decrease the complications 
associated with plasma exchange such as coagulopathy and transfusion reactions. 
 
 
 
Fig. 4. Schematic presentation of double filtration plasmapheresis (DFPP). In DFPP, plasma 
separated with a plasma separator (1st filter) passes through the plasma component 
separator with a small pore size (2nd filter). Molecules that are larger than the pore size such 
as immunoglobulins are removed, and smaller molecules such as albumin are returned to 
the patient. 
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4. Determination of isoagglutinin titer 
To reduce isoagglutinin titers prior to ABO-I kidney transplantation, preparative regimens 
including plasmapheresis, DFPP, or immunoadsorption and immunosuppressive therapy 
have been used. The clinical significance of isoagglutinin titer in ABO-I kidney 
transplantation is not entirely clear (Tobian et al., 2011). The goal of isoagglutinin titer to 
prevent hyperacute rejection is variable across transplantation centers, ranging from ≤ 1:8 to 
≤ 1:32 before transplantation (Crew & Ratner, 2010). However, minimal research has been 
performed to determine the optimal pretransplant titer. The possibility of AMR would 
decrease as anti-donor antibody titer decreases. In our institution, the titer is lowered to ≤ 
1:4 before transplantation. The measurement of isoagglutinin is known to be essential in the 
assessment of the efficacy of antibody removal, and the prediction of AMR (Kobayashi & 
Saito, 2006). Although most recipients with AMR had an elevated titer, the positive 
predictive value of a high titer for AMR was poor (Tobian et al., 2010). Thus, posttransplant 
titers should be monitored, but must be combined with the other factors assessing AMR. 
Accurate measurement of isoagglutinin titer is an important aspect for successful ABO-I 
kidney transplantation. If the isoagglutinin titer is underestimated compared to the actual 
titer of patient, we could consider a patient as safe for transplantation and it could lead to 
rejection or short duration of allograft survival (Crew & Ratner, 2010). IgM antibody mediates 
complement activation and endothelial damage in AMR, and it is more rapidly removed by 
plasmapheresis than IgG. However, IgG titers are more emphasized for patient eligibility, 
rejection risk, and plasmapheresis guidance. Reporting both IgM and IgG titers has been 
recommended by a working group from US centers (Montgomery et al., 2004). Importantly, 
measured titers are method-dependent and considerably variable according to assays. 
 
 
 Tube method Column  
agglutination 
Flow cytometry 
A column ingredient Not needed Sephadex gel 
or glass bead 
Not needed 
Use of RBC Yes Yes Yes 
Antihuman globulin Yes Yes No 
Secondary antibody No No Yes 
Deletion of IgM DTT or 2ME DTT or 2ME Not needed 
Interpretation Agglutination Agglutination Fluorescence detection 
Result Titer Titer MFIR or titer 
Instrument Not needed Not needed Needed 
Cost Low Intermediate Relatively high 
Assay time 30 - 60 min 30 - 60 min 1- 2 hours 
DTT, dithiothreitol; 2ME, 2-mercaptoethanol; MFIR, mean fluorescence intensity ratio. 
Table 1. Various assays for measurement of isoagglutinin titer 
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There are several options for the measurement of isoagglutinin titers: conventional tube 
method, gel or bead column agglutination method, and flow cytometry (Krishnan et al., 
2008; Stussi et al., 2005). These three methods are summarized in Table 1. In addition, 
enzyme-linked immunosorbent assay technique (Lindberg et al., 2011; Rieben et al., 1991), 
surface plasmon resonance (Kimura et al., 2005; Yurugi et al., 2007), and KODE technology 
(Frame et al., 2007) were developed, although these methods are not routinely available in 
most institutions. 
4.1 Conventional tube method 
The conventional tube method has been used in most institutions for the semiquantitative 
measurement of isoagglutinin titers. IgG and IgM can be measured together, and if 
dithiothreitol or antiglobulin reagents are used, they can be measured separately. In general, 
recipient serum is serially diluted and incubated with RBC aliquots of the appropriate blood 
type in a test tube for about 10 minutes at room temperature. After the mixture is 
centrifuged, macroscopic agglutinations of RBCs are checked for IgM detection. For IgG 
detection, additional testing with antihuman globulin is performed to check the 
agglutination. Titers are determined as the highest dilution that produces 1+ macroscopic 
agglutination. However, technical variables greatly affect the results, and care should be 
taken to achieve the most uniform practice (Roback, 2008). Considerable inter-examiner 
variability may occur, because the titer is determined mainly by visual observation of 
agglutinated RBCs in tubes. Inter-institutional difference can also occur possibly due to 
variations in procedures and lack of assay standardizations. 
A recent study reported the results of isoagglutinin titers from 26 different labs using sera 
from six patients of different blood groups (Kobayashi & Saito, 2006). In this report, inter-
institutional variation between maximum and minimum value reached as much as 32-fold 
in IgM and 256-fold in IgG. These variations seemed to be due to different techniques 
between laboratories, but considerable variation was still noted after standardization of 
techniques. Another report also showed a large variation of isoagglutinin titers (a median 
three-fold difference) among three centers performing ABO-I kidney transplants in 
Germany and Sweden (Kumlien et al., 2007). In this report, gel hemagglutination technique 
significantly decreased inter-center difference (a median one titer difference) compared with 
tube methods. 
4.2 Gel or bead column agglutination 
In gel or bead column agglutination method, a cassette (or card) containing gels or beads is 
used. Commercially available assays include DiaMed ID Micro Typing system (Bio-Rad, 
Hercules, CA, USA), BioVue System (Ortho Clinical Diagnosis, Raritan, NJ, USA), or 
Olympus ID-Micro Typing System (Olympus Co., Tokyo, Japan). In these assays, plasma 
from the patient is stepwise diluted 1:2 with normal saline or phosphate buffered saline and 
packed RBCs are used to make a suspension with cell stabilization solution. In each 
incubation well, recommended cell suspension is mixed with diluted plasma. After 
incubation and centrifugation, agglutination is observed in card or cassette. In column 
agglutination method, negative (unagglutinated) test cells pellet to the bottom of the 
column, and positive (agglutinated) cells are captured at the top of or within the body of 
column (Fig. 5). The gel or bead particles trap the RBC agglutinates as a filter during 
centrifugation. The agglutination is graded from 0 to 4 +, and inverted value of the highest 
plasma dilution that gives a 1+ agglutination reaction is interpreted as the titer (Kumlien et 
al., 2007). 
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Fig. 5. Interpretation of column agglutination method. The agglutination is graded from 
0 to 4+.  
4.3 Flow cytometry 
In flow cytometry method, quantifications of anti-A/B IgG and IgM are performed using 
fluorescence conjugated, anti-human IgG and IgM as secondary antibodies. A mixture of 
RBC suspension and recipient serum is transferred into the test tube and incubated (at 37°C 
in a CO2 incubator for IgG antibody; and at room temperature, for IgM antibodies). After 
washing, fluorescence conjugated, anti-human IgG and IgM secondary antibodies are added 
in test tube. After incubation and washing steps, binding of anti-A/B antibody is measured 
by flow cytometry. Human AB serum, which is further depleted by incubation with highly 
concentrated A and B RBCs, can be used as a negative control, and human serum of blood 
group O is used as a positive control. Commercially available O RBCs with information of 
antigen expression are also helpful for the detection of irregular antibodies (Stussi et al., 
2005). 
Using undiluted serum, quantification of anti-A/B antibody can be determined by 
calculation of the geometric mean fluorescence intensity ratio (MFIR). This value is 
calculated by dividing the geometric mean fluorescence intensity of test sera with that of 
negative control. One study reported that the correlation coefficient between MFIR using 
flow cytometry and isoagglutinin titer was 0.870 for IgM and 0.783 for IgG (Stussi et al, 
2005). For determination of titer using flow cytometry, recipient serum is serially diluted 
with normal saline solution (2% bovine serum albumin, 0.1% azide). After incubation and 
washing, secondary antibody is added. After reaction, binding of antibody is determined by 
flow cytometry. A gated value above assigned cut-off (5% for example) is regarded as 
positive serum dilution. In a study comparing the reproducibility of the results performed 
by various assays, flow cytometry showed excellent reproducibility and no measurement 
deviation was noted, whereas gel column agglutinin assay and tube technique showed two-
fold and four-fold differences, respectively (Tanabe, 2007b). However, flow cytometry assay 
needs the flow cytometry instrument, and the reagents are relatively expensive. 
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5. Conclusion 
The ABO blood group barrier is now being crossed in the field of transplantation, and ABO-
I kidney transplantation is becoming more common worldwide. Removing the ABO barrier 
can expand the donor pool and increase the availability of organs for transplantation. 
Moreover, it can decrease the time on the organ waiting list, and eventually facilitate the 
timely transplantation before comorbid conditions develop in the patients. Currently 
observed long-term results of ABO-I kidney transplantation are similar to those of ABO-
compatible kidney transplantation. With the application of adequate antibody reducing 
strategies, future results would be more promising. To promote accomodation and to 
prevent acute complement-mediated graft injury, methods for preventing and treating AMR 
are still needed. Researches for the insights into the mechanism of accomodation will 
provide us a scientific basis for the development of innovative approaches for the better 
outcome of ABO-I kidney transplantation.  
As the number of ABO-I transplantation increases, there is a need of the optimal methods 
for ABO isoagglutinin titer for the effective monitoring of ABO-I transplanted patients. 
Compared with the conventional test tube method, gel card or flow cytometric 
measurement can provide more accurate and objective results. However, reproducibility, 
interpretation, and standardization of isoagglutinin titration methods are still unsatisfactory, 
and further researches should be performed to determine the optimal method for ABO 
antibody titer assessment. There are also several promising techniques under development, 
focused on the endothelium, enzymes, or blocking antibodies. Ongoing improvement of 
promising modalities could make more successful transplantation outcomes in this field.  
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